Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljae042 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Hans Christian Ring und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermato-Venereology and Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Ustekinumab, Hidradenitis Suppurativa, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
This nationwide cohort study included 452 patients (873 treatment series) and reported drug survival data on patients with hidradenitis suppurativa treated with biologics such as adalimumab, infliximab, ustekinumab and secukinumab. The median drug survival time for adalimumab was approximately 8 months, but bio-naïve patients had a significantly longer drug survival time compared with non-naïve patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermato-Venereology and Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.
- COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital.
- The Charles Centre, Department of Dermatology, St. Vincent's University Hospital, Dublin, Ireland.
- Department of Dermatology and Academic Wound Healing, Institute of Infection and Immunity, Cardiff University, Cardiff, UK.
- Department of Dermatology, University of Zürich, Zürich, Switzerland.
- Department of Dermatology, University of Miami Miller School of Medicine, Los Angeles, CA, USA.
ORCID-Profile: Hans Christian Ring, Brian Kirby, John R Ingram, Julia-Tatjana Maul, Alexander Egeberg
Zitieren
APA
Ring, H. C., Thorsen, J., Kirby, B., Ingram, J. R., Rosenø, N. A. L., Holgersen, N., Nielsen, V. W., Thein Aagaard, D. N., Maul, J. T., Wu, J. J., Thyssen, J. P., Egeberg, A., & Thomsen, S. F. (2024). Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae042
Vancouver
Ring HC, Thorsen J, Kirby B, Ingram JR, Rosenø NAL, Holgersen N, et al. Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae042
BibTeX
@article{Ring2024,
author = {Ring, Hans Christian and Thorsen, Jonathan and Kirby, Brian and Ingram, John R and Rosenø, Nana Aviaaja Lippert and Holgersen, Nikolaj and Nielsen, Valdemar W and Thein Aagaard, David Nikolai and Maul, Julia-Tatjana and Wu, Jashin J and Thyssen, Jacob P and Egeberg, Alexander and Thomsen, Simon F},
title = {Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljae042}
}
EUVIMED